Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. The funds will support an upcoming clinical trial aimed […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!